Quarterly report pursuant to Section 13 or 15(d)

Investments - Narrative (Details)

v3.19.2
Investments - Narrative (Details)
$ in Millions
6 Months Ended
Jun. 30, 2019
USD ($)
shares
Investment [Line Items]  
Total assets of equity method investees | $ $ 183.7
Total (liabilities) of equity method investees | $ (51.9)
Net losses of equity method investees | $ (23.3)
Market value | $ $ 12.5
Pharmsynthez  
Investment [Line Items]  
Ownership percentage, equity method 9.00%
Cocrystal  
Investment [Line Items]  
Ownership percentage, equity method 8.00%
Number of shares into which warrants may be converted (in shares) 33,000
Non-Invasive Monitoring Systems, Inc.  
Investment [Line Items]  
Ownership percentage, equity method 1.00%
Neovasc  
Investment [Line Items]  
Ownership percentage, equity method 5.00%
InCellDx, Inc  
Investment [Line Items]  
Ownership percentage, equity method 29.00%
Number of shares into which warrants may be converted (in shares) 700,000
BioCardia, Inc.  
Investment [Line Items]  
Ownership percentage, equity method 5.00%
Ownership percentage 5.00%
Number of shares into which warrants may be converted (in shares) 47,000
Investment options, vested (in shares) 23,000
Xenetic Biosciences, Inc.  
Investment [Line Items]  
Ownership percentage, equity method 4.00%
Number of shares into which warrants may be converted (in shares) 40,000
Phio Pharmaceuticals  
Investment [Line Items]  
Ownership percentage 0.20%
Number of shares into which warrants may be converted (in shares) 22,000
VBI Vaccines Inc  
Investment [Line Items]  
Ownership percentage 7.00%
ChromaDex  
Investment [Line Items]  
Ownership percentage 0.10%
MabVax  
Investment [Line Items]  
Ownership percentage 1.00%
Eloxx Pharmaceuticals  
Investment [Line Items]  
Ownership percentage 4.00%
Zebra  
Investment [Line Items]  
Ownership percentage, equity method 29.00%
Series A-2 Preferred Stock | Zebra  
Investment [Line Items]  
Investment owned (in shares) 1,260,000
Restricted Stock | Zebra  
Investment [Line Items]  
Shares received as a gift (in shares) 900,000